Reimbursement Updated June 19, 2026

State Biomarker-Testing Coverage Laws: A 2026 Reference for Labs and Clinics

More than two dozen states have enacted laws requiring health plans to cover biomarker testing supported by medical evidence, but those mandates generally do not reach self-funded ERISA employer plans. This reference explains what the laws require, who they bind, and why coverage still varies in practice.

A lung-cancer patient in Phoenix and a lung-cancer patient in Tulsa can have the same diagnosis, the same recommended comprehensive genomic profiling, and the same commercial insurance carrier, and still get two different answers when the lab bills for the test. One reason is that biomarker-testing coverage in the United States is no longer governed by a single rule. It is governed by a fast-growing patchwork of state laws, layered on top of federal preemption that quietly exempts a large share of patients from those very laws.

For a lab director or a revenue-cycle leader, that patchwork is not trivia. It decides which appeals will win, which patients you can reassure, and which "covered by law" claims will still be denied. This article is a working reference: what these laws require, which states have them, who they bind, and the one carve-out that trips up almost everyone.

Disclaimer: This article is educational and is not legal, billing, or coverage advice. State biomarker laws change frequently, vary in their exact language, and are interpreted by regulators and courts; statutory text and effective dates are the only authoritative sources. Nothing here guarantees coverage of any test for any patient or plan. Verify the current statute and regulations in your state and consult qualified legal and compliance counsel before acting. Use this information at your own risk.

What a "biomarker-testing coverage law" actually does

The wave of state laws traces largely to model legislation promoted by the American Cancer Society Cancer Action Network (ACS CAN) and allied groups. The core idea is consistent across states even though the wording differs: a state-regulated health plan must cover biomarker testing used for the diagnosis, treatment, appropriate management, or ongoing monitoring of a patient's disease, when the test is supported by medical and scientific evidence.

That evidence standard is the heart of the statute. Most states define qualifying evidence by reference to a defined list of authorities. According to a peer-reviewed analysis published in Health Affairs Scholar (2024), every state law except Louisiana's points to the same family of criteria: FDA approval or clearance of the test, use of a test in connection with an FDA-approved drug that requires the testing for treatment decisions or monitoring, Medicare national and local coverage determinations, and nationally recognized clinical practice guidelines. In oncology, those guidelines typically mean NCCN and ASCO, which is how a non-FDA-reviewed assay can still meet the bar.

Two boundaries matter as much as the mandate itself. First, these laws generally do not require coverage of screening biomarker tests; the same analysis found no state mandating screening coverage, and three states (California, Kentucky, and Nevada) explicitly carve screening out. Second, many of the laws also constrain how plans may use prior authorization, with some states limiting or prohibiting prior authorization for biomarker testing in advanced disease. California's law, for example, has been described as barring prior authorization for biomarker testing in enrollees with advanced or metastatic Stage III or IV cancer. The details vary by state, so the existence of a law does not automatically mean "no prior auth."

Comprehensive vs. narrow: not all laws are equal

It is tempting to treat "my state has a law" as a binary, but the laws differ enough that the distinction is operational. Researchers analyzing the statutes split them into comprehensive laws, which mandate coverage of biomarker testing across all state-regulated plans, and narrower laws, which reach fewer plan categories, address only prior authorization, or limit the populations or disease stages covered.

As of mid-May 2025, that Health Affairs Scholar analysis counted 16 states with comprehensive laws and 5 with narrower laws, plus roughly 13 states with legislation introduced but not yet enacted. The comprehensive group it identified included states such as Arizona, California, Illinois, Louisiana, and Rhode Island; the narrower group included states such as Arkansas, Colorado, and Florida (Louisiana appears in both characterizations in the literature, a reminder that these labels are analytic judgments, not statutory labels). The practical takeaway: read your own state's statute rather than assuming a neighbor's scope.

The by-state snapshot (mid-2026)

The table below reflects states that authoritative trackers identify as having enacted biomarker-testing coverage legislation. It is a snapshot, not a guarantee, and it changes nearly every legislative session. The "scope" column reflects the comprehensive-vs-narrow characterization from the 2024 peer-reviewed analysis where available; states added afterward are marked "enacted (verify scope)" because their classification was not part of that dataset.

State Status (as of mid-2026) Scope characterization
Arizona Enacted Comprehensive
Arkansas Enacted Narrower
California Enacted Comprehensive
Colorado Enacted Narrower
Connecticut Enacted Enacted (verify scope)
Florida Enacted Narrower
Georgia Enacted Enacted (verify scope)
Illinois Enacted Comprehensive
Indiana Enacted Enacted (verify scope)
Iowa Enacted Enacted (verify scope)
Kentucky Enacted Enacted (verify scope)
Louisiana Enacted Comprehensive / narrower (see text)
Maryland Enacted Enacted (verify scope)
Minnesota Enacted Enacted (verify scope)
Mississippi Enacted ("Jill's Law," 2026) Enacted (verify scope)
Nebraska Enacted Enacted (verify scope)
New Jersey Enacted Enacted (verify scope)
New Mexico Enacted Enacted (verify scope)
New York Enacted Enacted (verify scope)
Oklahoma Enacted Enacted (verify scope)
Pennsylvania Enacted Enacted (verify scope)
Rhode Island Enacted Comprehensive
Tennessee Enacted Enacted (verify scope)
Texas Enacted (effective Jan 1, 2026) Enacted (verify scope)

Sources: ACS CAN biomarker-testing tracker (state list current through 2026); Health Affairs Scholar analysis (scope characterization, data as of mid-May 2025); Texas effective date per the enacting bill. The ACS CAN tracker also reports biomarker bills introduced in 2026 in states including Delaware, Hawaii, Maine, Massachusetts, New Hampshire, North Carolina, Ohio, Vermont, and Washington; introduction is not enactment, so those are excluded from the table above. Confirm any state's current status and effective date against its statute before relying on it.

Counted together, the enacted list above is roughly two dozen states (about 24) as of mid-2026, consistent with AIS Health/MMIT's reporting that "more than 20 states" now mandate coverage. Treat the exact number as a moving target.

The carve-out that matters most: ERISA and self-funded plans

Here is the single most important operational fact in this entire area, and the one that most often surprises clinicians and patients: state biomarker laws do not reach self-funded employer health plans.

State insurance mandates apply to insurance that the state regulates. That means fully-insured commercial plans sold in the state must comply, and the biomarker laws frequently extend to the state's Medicaid program as well (with state-specific exceptions; the Health Affairs Scholar analysis noted that Arkansas explicitly excludes Medicaid, and that Louisiana and Rhode Island statutes do not mention it). State employee plans typically comply where the statute says so.

But self-funded (also called self-insured) employer plans are different animals. In a self-funded plan, the employer bears the claims risk and merely hires an insurer or third-party administrator to process claims. These plans are governed by the federal Employee Retirement Income Security Act (ERISA), and ERISA broadly preempts state insurance mandates. A state cannot order a self-funded ERISA plan to cover biomarker testing the way it can order a fully-insured plan. This is not a loophole specific to biomarker laws; it is the long-standing structure of U.S. insurance regulation, and it applies to most state benefit mandates.

The scale is what makes this decisive rather than academic. A majority of U.S. workers with employer-sponsored coverage are in self-funded plans, commonly cited in the low-to-mid 60% range of covered workers. So even in a state with a strong, comprehensive biomarker law, a large fraction of commercially insured patients may sit outside the mandate's reach. The law is real; its reach is narrower than the headline suggests.

The trap is that you usually cannot tell the two apart from the insurance card. A patient with a major-carrier card in a mandate state may have a fully-insured plan that must comply, or a self-funded plan administered by that same carrier that does not. Determining plan type, often by checking eligibility data, ASO indicators, or asking the plan directly, is the difference between an appeal grounded in state law and one that has to stand on medical-necessity and guideline evidence alone.

Why coverage still varies even when a law applies

Suppose you have confirmed a fully-insured plan in a comprehensive-mandate state. You still are not guaranteed payment, and labs in mandate states continue to see denials. Several reasons recur:

  • The evidence standard is a gate, not a rubber stamp. The plan must cover the test when supported by medical and scientific evidence as the statute defines it. A test that does not map cleanly to FDA labeling, a Medicare coverage determination, or a recognized guideline can be denied as not meeting the standard, and that denial may be lawful.
  • Documentation decides borderline cases. Stage, diagnosis, intent (treatment selection vs. screening), and the clinical rationale have to be in the record. Mandates do not cover screening, so a test that looks like screening on the claim can be denied even when the underlying intent was treatment selection.
  • Prior authorization persists where the law allows it. Where a state did not bar prior authorization (or barred it only for specific stages), plans may still require it, and a missed authorization is still a denial.
  • Implementation lags the statute. Regulators issue bulletins clarifying that the biomarker law governs and that plans may not layer on extra criteria, which only happens because plans were, in fact, layering on extra criteria. The law on the books and the medical policy in production are not always in sync on day one.

None of this makes the laws toothless. In the right plan, the statute is a powerful appeal argument: it lets you assert that the plan is required to cover an evidence-supported test and may not impose criteria the statute forecloses. But "covered by law" and "paid on first submission" are different claims, and conflating them is how revenue leaks.

What this means operationally

The honest summary is uncomfortable: to know whether a given biomarker test is covered, you need to know the patient's state, the patient's plan type (fully-insured, self-funded/ERISA, or Medicaid), the specific statute's scope in that state, the evidence basis for the test, and the plan's current medical policy and prior-auth rules. Each of those can change independently, and the state count itself rises most legislative sessions.

That is a lot of jurisdiction-specific, plan-specific, constantly-moving logic to maintain by hand, especially for a lab that draws specimens from many states. A spreadsheet captured last quarter is already drifting out of date. This is precisely the kind of per-state, per-plan-type coverage logic that Converus is built to track so revenue-cycle and market-access teams can act on the current rule rather than last year's memory of it. Whatever tooling you use, the discipline is the same: treat biomarker coverage as a function of state and plan type, verify against the live statute and policy, and never assume a law you read about covers the patient in front of you.

Sources

This is a point-in-time snapshot. The number of states, their scope, and effective dates change frequently. Verify current status against the relevant statute and your state insurance regulator before relying on any item above.

Frequently Asked Questions

How many states have biomarker-testing coverage laws as of 2026?
As of mid-2026, the American Cancer Society Cancer Action Network's tracker lists roughly two dozen states (around 24) that have enacted biomarker-testing coverage legislation, with more bills introduced in 2026. A peer-reviewed analysis published in 2024 distinguished comprehensive laws (covering all state-regulated plans) from narrower ones; as of mid-May 2025 it counted 16 comprehensive and 5 narrow laws. Because the count rises almost every legislative session, always confirm a specific state's current status against its statute before relying on it.
Do state biomarker laws apply to self-funded employer (ERISA) health plans?
Generally no. State insurance mandates bind state-regulated, fully-insured commercial plans, and the biomarker laws often extend to state Medicaid programs, but self-funded (self-insured) employer plans are governed by the federal ERISA statute and are largely exempt from state insurance mandates. Because a majority of U.S. workers with employer coverage are in self-funded plans, a large share of commercially insured patients sit outside these mandates. You usually cannot tell a fully-insured plan from a self-funded one by the card alone, which is the central operational caveat.
What do these laws actually require plans to cover?
Most require coverage of biomarker testing for diagnosis, treatment, management, or monitoring of a disease when the test is supported by medical and scientific evidence. States typically define that evidence by reference to FDA approval or FDA-labeled companion diagnostics, Medicare national or local coverage determinations, and nationally recognized clinical practice guidelines (such as NCCN). The laws do not generally mandate coverage of screening tests, and several states explicitly exclude screening.
If my state has a law, is coverage guaranteed?
No. A mandate sets a floor for the plans it binds, but coverage still depends on plan type (fully-insured vs. self-funded), whether the test meets the statute's evidence standard, documentation of medical necessity, and any permitted prior-authorization rules. Labs continue to see denials even in mandate states, so the law is a strong argument on appeal, not a guarantee of payment.
← Back to Knowledge Base